PSNL - Personalis, Inc.

QQQ $ 610.70 $ -0.16 (-0.03 %)

DIA $ 469.29 $ 2.20 (0.47 %)

SPY $ 671.31 $ -0.01 (0 %)

TLT $ 91.98 $ 0.45 (0.49 %)

GLD $ 379.12 $ -25.91 (-6.43 %)

Previous Close

$ 9.57

Open

$ 9.90

Bid

$ 9.61 x 10

Ask

$ 10.30 x 100

Day's Range

$ 9.55 - $ 10.33

52 Week Range

$ 2.83 - $ 10.95

Volume

1,478,558

Average Volume

Market Cap

848.64M

Beta (5Y Monthly)

$ 1.84

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-05-2025	06-30-2025	10-Q
2	05-06-2025	03-31-2025	10-Q
3	02-27-2025	01-01-1970	10-K
4	11-06-2024	09-30-2024	10-Q
5	08-07-2024	06-30-2024	10-Q
6	05-08-2024	03-31-2024	10-Q
7	02-28-2024	12-31-2023	10-K
8	11-07-2023	09-30-2023	10-Q
9	08-08-2023	06-30-2023	10-Q
10	05-03-2023	03-31-2023	10-Q
11	02-23-2023	12-31-2022	10-K
12	11-02-2022	09-30-2022	10-Q
13	08-03-2022	06-30-2022	10-Q
14	05-04-2022	03-31-2022	10-Q
15	02-24-2022	12-31-2021	10-K
16	11-04-2021	09-30-2021	10-Q
17	08-04-2021	06-30-2021	10-Q
18	05-05-2021	03-31-2021	10-Q
19	02-25-2021	12-31-2020	10-K
20	11-05-2020	09-30-2020	10-Q
21	08-06-2020	06-30-2020	10-Q
22	05-07-2020	03-31-2020	10-Q
23	03-25-2020	12-31-2019	10-K
24	11-13-2019	09-30-2019	10-Q
25	08-13-2019	06-30-2019	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Personalis Announces Phase 3 LAURA Trial D...
10/16/2025 13:08:22

Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca ph...

Personalis And Yale Cancer Center Collabor...
09/10/2025 20:10:39

HC Wainwright & Co. Reiterates Buy on Pers...
09/08/2025 10:58:41

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Personalis (NASDAQ:PSNL) with a Buy and maintains $8.5 pri...

Personalis Announces New Data From Astraze...
09/03/2025 20:19:09

Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca ph...

Personalis Expands VA Million Veteran Prog...
08/22/2025 11:03:40

12 Health Care Stocks Moving In Wednesday'...
08/06/2025 17:06:59

HC Wainwright & Co. Maintains Buy on Perso...
08/06/2025 12:44:20

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Personalis (NASDAQ:PSNL) with a Buy and lowers the price ta...

super-micro-computer-posts-downbeat-q4-results-joins-personalis-snap-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session

Super Micro Computer Posts Downbeat Q4 Res...
08/06/2025 12:11:55

12 Health Care Stocks Moving In Wednesday'...
08/06/2025 12:08:40

why-astera-labs-shares-are-trading-higher-by-over-17-here-are-20-stocks-moving-premarket

Why Astera Labs Shares Are Trading Higher ...
08/06/2025 09:35:31

12 Health Care Stocks Moving In Tuesday's ...
08/05/2025 21:07:20

Personalis Lowers FY2025 Sales Guidance fr...
08/05/2025 20:03:14

Personalis (NASDAQ:PSNL) lowers FY2025 sales outlook from $80.000 million-$90.000 million to $70.000 million-$80.000 million vs...

Personalis Sees Q3 Sales $12.000M-$14.000M...
08/05/2025 20:02:45

Personalis (NASDAQ:PSNL) sees Q3 sales of $12.000 million-$14.000 million vs $18.874 million analyst estimate.

Personalis Q2 EPS $(0.23) Beats $(0.24) Es...
08/05/2025 20:02:07

Personalis (NASDAQ:PSNL) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.24) by...

Earnings Scheduled For August 5, 2025
08/05/2025 08:32:54

cramer-says-tesla-dominates-while-ouster-is-too-speculative

Cramer Says Tesla Dominates While Ouster I...
07/10/2025 12:07:44

Jim Cramer advises against investing in Tempus AI due to its ongoing losses and suggests Pan American as a profitable alternat...

12 Health Care Stocks Moving In Wednesday'...
07/09/2025 21:06:40

Personalis and Tempus Extend Partnership T...
07/09/2025 20:01:13

Collaboration extension through 2029 accelerates access to MRD technology across four major cancer typesPersonalis, Inc. (NASDA...

Personalis Presents New Results From CALLA...
06/03/2025 20:02:29

Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new results...

Personalis Presents New Clinical Results F...
06/02/2025 20:02:10

Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new clinica...